Investment
Features
FeesSafety
Academy
More
Pluang+

Compare JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) vs Medpace Holdings Inc (MEDP) Price & Performance

JPMorgan Nasdaq Equity Premium Income ETFTrade
Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

JPMorgan Nasdaq Equity Premium Income ETF vs Medpace Holdings Inc — how do they compare? JPMorgan Nasdaq Equity Premium Income ETF trades at $59.4, while Medpace Holdings Inc trades at $528.29 (market cap $15.08B). Which is the better fit depends on your goals.

JEPQMEDP
Sector
Income / Options OverlayTechnology
52-Week High
$61.46$620.59
52-Week Low
$53.77$308.88
Market Cap
$15.08B
Enterprise Value
$14.55B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

JPMorgan Nasdaq Equity Premium Income ETF

JEPQ trades at $58.59, up 0.14% with a bearish technical signal from moving averages. The ETF focuses on Nasdaq-100 exposure with covered-call strategies, generating monthly income through dividends. Recent distributions include $0.64, $0.56, and $0.59 per share, highlighting its income-oriented approach. Technical indicators show neutral oscillators but overall bearish momentum with key support at $57.

The outlook remains cautious due to technical bearishness and capped upside from covered calls. Investment appeal centers on high distribution yields for income-focused investors, though performance may lag pure Nasdaq-100 ETFs during rallies. Risks include strategy underperformance in bull markets and dependency on options income sustainability.

Medpace Holdings Inc

MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.

MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About JPMorgan Nasdaq Equity Premium Income ETF

JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.

Read more on JEPQ

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP